USA flag logo/image

An Official Website of the United States Government

System for PCS Agencies to Monitor, Investigate and Respond to Elder Safety…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
R44AG044157
Solicitation Year:
2013
Solicitation Topic Code:
NIA
Solicitation Number:
PA12-088
Small Business Information
ADVANCED GENOMIC TECHNOLOGY, LLC
Room 118, 580 South Preston Street LOUISVILLE, KY 40202-1756
View profile »
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: System for PCS Agencies to Monitor, Investigate and Respond to Elder Safety Risks
Agency: HHS
Contract: 1R44AG044157-01A1
Award Amount: $199,666.00
 

Abstract:

DESCRIPTION (provided by applicant): This project aims to generate blood tests for: 1. mild cognitive impairment (MCI), and 2. conversion risk from MCI to full-blown Alzheimer's disease (AD). We have reported that systemic footprints, increases in key micro- RNA (miR) levels, are identifiable in AD blood samples; here we suggest that this is also true for MCI, the pre- AD phase. Our recent results suggest two stages of cognitive decline continuum: Stage 1, for key microRNAs increased from circulating bloodof normal elderly controls (NEC) to that of MCI patients, but not further to AD; and Stage 2, for specific circulating blood microRNA increases from MCI to AD. This led us to suggest our mo- del: Stage 1 circulating microRNAs as MCI-specific biomarkers andStage 2 circulating microRNAs as biomark- ers for conversion of MCI to AD. Prototypes of these biomarkers are: Stage 1, miR-181b increases from NEC to MCI levels, but not further in AD plasma samples; Stage 2, increased miR-34a and miR-34c levels, observed only from MCI to AD, but not from NEC to MCI plasma. These results suggest that the MCI cognitive decline may start with increased Stage 1 microRNAs' expression, then Stage 2 increases add insult to injury; the for- mer being MCI-specific biomarkers, andthe latter specific for AD and/or converter patients. Our goal is then to establish two sets of stage-specific biomarkers, based on: a. highly reproducible data for identified blood micro- RNAs; b. training datasets for next-stage development for FDA approval; and c. validated specificity for de- mentia due to AD, in contrast to other types of dementia. Toward this end, Phase I will study 30 archived sam- ples each of MCI, NEC, and AD blood, to attain: Aim 1, establishing the reproducibility of our protocol for opti- mal blood microRNA assays, and identifying lead microRNAs' origins by determining concordance and/or dis- cordance among the above three microRNAs' increases in three circulating blood compartments: peripheral blood mononuclear cells (PBMC), plasma/serum, and its derivative, exosomes; and Aim 2, identifying other members of four lead array-profiled and PCR-validated microRNA families: miR-34, -181, 200, and Let-7, to expand our pool of candidate Stage 1 and Stage 2 biomarkers. In Phase II, Aim1 expands to a larger cohort of 200 MCI patients' samples, to establish a Stage 1 biomarker training dataset tracing 21 microRNAs of these 4 families; Aim 2 establishes a repertoire of Stage 2 biomarkers, in archived specimens from 22 MCI subjects in our study, 12 of whom have converted to AD within the past decade, by comparing freshly collected with archived blood samples from converters versus non-converters by qPCR assays of the 21 listed miRNAs, and array profiling to identify additional novel ones; and Aim 3 establishes the identified biomarkers as specific for AD in contrast with non-AD dementias, i.e. Frontotemporal (FTD), Lewy body (LBD), and Parkinson's disease (PD) with dementia (PDD). Success of this project will provide blood miRNA-based diagnostics for MCI, and predict conversion from MCI to AD, unprecedented tests to monitor disease onset, progression, and drug efficacy for novel therapies to retard the decline of MCI to bona fide AD. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE:Like Alzheimer's disease (AD) health care, mild cognitive impairment (MCI) due to AD suffers from the lack of a noninvasive blood test, which is a major roadblock to MCI diagnosis; in its absence, the disease is largely de- fined by neuropsychological assessment and costly MRI imaging, and secondarily by identified cerebrospinal fluid biomarkers, a less ideal approach due to its invasive nature. This project aims to generate cost-effective, noninvasive blood tests for serial diagnosis and staging of MCI andits conversion to full-blown AD, based on unique biomarkers, microRNA expressions whose levels in circulating blood are 'footprints' of disease patho- genesis, reflecting cognitive declin in brain. Quantitative metrics of circulating key microRNAs may serve as numerical indices for diagnosis of MCI and prognosis of conversion to AD, as well as objective drug efficacy measurements for novel therapies to retard the further decline of these victims from developing full-blown Alzheimer's disease, and thus halting the tidal wave of a fast-increasing aging population suffering this devastating, mind-robbing peril.

Principal Investigator:

Eugenia Wang
502-852-8331
ewangagt@gmail.com

Business Contact:

Eugenia Wang
502-228-5438
ewangagt@gmail.com
Small Business Information at Submission:

ADVANCED GENOMIC TECHNOLOGY, LLC
Room 118, 580 South Preston Street LOUISVILLE, KY 40202-1756

EIN/Tax ID: 126292862
DUNS: N/A
Number of Employees: N/A
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No